This week, Ceptaris was granted approval by the FDA for its topical chemotherapy drug used to treat lymphoma. The gel, which was previously administered intravenously, is applied directly to the skin, making it the first of its kind to be approved for topical treatment.
The FDA granted market approval for Pennsylvania-based Ceptaris' orphan cancer drug Valchlor, designed to treat stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL), itself a rare form of non-Hodgkin's lymphoma, for patients who have received prior skin-directed therapies. Because CTCL is characterized by lesions on the skin caused by malignant T cells, topical treatments of mechlorethamine--otherwise known as nitrogen mustard--have been used before, but Valchlor is the first with U.S. approval.
This new treatment could help minimize doctor's visits, and cut costs. How else can this type of treatment affect a patients experience? Want to learn more about Drug Delivery technology? Visit our homepage and opt- in to receive updates all year round.